10-Q/A: The Joint Corp. Restates Q1 2025 Financials, Cites Material Weakness

The Joint Corp. filed an amended quarterly report, restating Q1 2025 financial statements due to material errors in asset valuation and disclosing a material weakness in internal controls.

Summary

• The Joint Corp. (JYNT) filed an amended Quarterly Report on Form 10-Q/A for the three months ended March 31, 2025, to restate previously issued financial statements.
• The restatement was necessary due to a material error in the valuation methodology for certain assets held for sale within discontinued operations, which was not consistent with GAAP.
• Management concluded that internal control over financial reporting was not effective as of March 31, 2025, identifying a material weakness in accounting for complex areas, specifically impairment related to assets held for sale.
• The restatement resulted in an increase in net income for the three months ended March 31, 2025, from $801,430 to $967,796.
• Total assets as of March 31, 2025, increased by $2,899,316 to $80,093,309, and total equity increased by the same amount to $22,837,392.
• The company is pursuing a strategy to refranchise its full portfolio of company-owned or managed clinics, having received draft letters of intent for the entire portfolio.
• Continuing operations saw total revenues increase by 7.3% to $13.1 million for Q1 2025 compared to Q1 2024, driven by growth in royalty, franchise, advertising fund, and software fees.
• Loss from continuing operations increased by 59.1% to $(678,534) in Q1 2025, primarily due to a significant increase in selling and marketing expenses (up 56.6% to $3.5 million) related to digital marketing transformation efforts.
• System-wide sales for all clinics grew 5.0% to $132.6 million, and comparable same-store sales for clinics open at least 13 months increased 3.1%.
• Mature clinics (open 48 months or more) experienced a 1.7% decrease in comparable same-store sales.
• The number of franchised clinics opened in Q1 2025 was 5, a decrease from 23 in Q1 2024, and clinic licenses sold decreased from 15 to 9.
• Cash and cash equivalents stood at $21.9 million as of March 31, 2025, with $3.7 million used in operating activities during the quarter.

Sentiment

Score: 3

Explanation: The restatement and material weakness in internal controls are severe negative indicators, outweighing the positive aspects of revenue growth and the refranchising strategy. While the restatement increased net income, the underlying control deficiencies are a major concern for financial reliability and investor confidence. The increased operating loss and slowdown in franchise development also contribute to a negative outlook.

Positives

• Restated net income for Q1 2025 increased by $166,366 to $967,796, improving the reported profitability.
• Total revenues from continuing operations increased by 7.3% to $13.1 million for Q1 2025, indicating strong underlying business growth in the franchise segment.
• Royalty fees and advertising fund revenue increased due to an expanding franchised clinic base and continued sales growth.
• System-wide sales grew 5.0% to $132.6 million, demonstrating overall brand strength.
• Comparable same-store sales for clinics open at least 13 months increased by 3.1%.
• General and administrative expenses decreased by 5.8% to $6.9 million, reflecting reduced payroll and employee compensation.
• The company's refranchising strategy for corporate clinics is progressing, with draft letters of intent received for the full portfolio, aiming to leverage franchise-building strength for long-term growth.
• Increased interest income from the deployment of cash into higher interest rate savings products contributed to other income (expense), net.

Negatives

• The necessity of a restatement for previously issued financial statements indicates a significant accounting error and raises concerns about financial reporting reliability.
• Management concluded that internal control over financial reporting was not effective as of March 31, 2025, due to a material weakness in accounting for complex areas, specifically asset impairment valuation.
• Loss from continuing operations increased by 59.1% to $(678,534) for Q1 2025, primarily driven by a substantial increase in selling and marketing expenses.
• Selling and marketing expenses surged by 56.6% to $3.5 million, indicating higher costs to acquire customers or build brand awareness.
• Franchised clinic openings decreased significantly to 5 in Q1 2025 from 23 in Q1 2024, and clinic licenses sold dropped from 15 to 9, suggesting a slowdown in franchise expansion.
• Comparable same-store sales for mature clinics (open 48 months or more) decreased by 1.7%, which could signal saturation or increased competition in established markets.
• The company used $3.7 million in cash from operating activities in Q1 2025, a notable shift from providing $2.8 million in the prior year period.
• The ongoing volatile macroeconomic environment, labor shortages, and inflation continue to pose headwinds to the business.

Risks

• The restatement of previously issued financial statements may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the stock price.
• A material weakness in internal controls over financial reporting exists, and failure to remediate it could negatively impact the ability to accurately report financial results, prevent fraud, or maintain investor confidence.
• Nationwide labor shortages may negatively impact the ability to recruit chiropractors and other qualified personnel, potentially limiting growth strategy and reducing net revenues.
• Inflation, leading to increased labor costs and interest rates, as well as changes to import tariffs, may reduce discretionary spending and negatively impact the business.
• Inability to successfully implement the growth strategy if franchisees cannot locate appropriate sites, obtain favorable lease terms, or attract patients.
• Limited experience operating company-owned or managed clinics in new geographic areas may prevent duplication of franchisee success.
• Short-selling strategies and negative opinions posted on the internet could drive down the market price of common stock and result in class action lawsuits.
• Failure to successfully design and maintain proprietary and third-party management information systems or implement new systems.
• Inability to properly maintain data integrity or strategically implement, upgrade, or consolidate existing information systems.
• Failure to continue selling franchises to qualified franchisees or franchisees not succeeding in developing profitable territories and clinics.
• New clinics may not reach profitability, and the company may not be able to maintain or improve revenues and franchise fees from existing franchised clinics.
• The highly competitive chiropractic industry, with many well-established independent competitors, could prevent market share increase or result in reduction.
• State administrative actions and rulings regarding the corporate practice of chiropractic and prepayment of chiropractic services may jeopardize the business model.
• Expected new federal regulations and state laws regarding joint employer responsibility could negatively impact the franchise business model, increasing potential liability.
• Increased regulatory focus on fair franchise practices could increase the risk of liability in disputes with franchisees and enforcement actions.
• Negative publicity or damage to reputation could adversely impact operations and financial position.
• IT security systems and those of third-party service providers may be breached, leading to civil liability and diminished public perception.
• Legislation and regulations, as well as new medical procedures and techniques, could reduce or eliminate competitive advantages.

Future Outlook

The company plans to continue its rapid and franchised-focused expansion of chiropractic clinics in key markets, aiming to be the leading provider and most recognized brand in the industry. It anticipates 2025 will remain a volatile macroeconomic environment, with continued headwinds from labor shortages and inflation. The refranchising of company-owned clinics is expected to generate value-creating capital allocation opportunities, including reinvestment in the brand, IT platforms, regional development territory repurchases, M&A, and/or a stock repurchase program. The company believes its existing cash, anticipated cash flows, and line of credit will be sufficient for the next 12 months, but acknowledges uncertainties could rapidly and materially deteriorate market conditions.

Management Comments

• "We will continue our rapid and franchised-focused expansion of chiropractic clinics in key markets throughout North America, and potentially abroad, as we seek to be the leading provider of chiropractic care in the markets we serve and to become the most recognized brand in our industry."
• "Our current strategy is to grow through the sale and development of additional franchises."
• "This refined strategy will leverage our greatest strength our capacity to build a franchise to drive long-term growth for both our franchisees and The Joint as a public company."
• "We have created a robust framework for the refranchising effort, organizing clinics into clusters, and generating comprehensive disclosure packets for marketing efficiency."
• "Our goal will be to generate significant processes that will provide us with value creating capital allocation opportunities."
• "We believe that we continue to have a sound business concept and will benefit from the fundamental changes taking place in the manner in which Americans access chiropractic care and their growing interest in seeking effective, affordable natural solutions for general wellness."
• "We anticipate that 2025 will continue to be a volatile macroeconomic environment."
• "While we anticipate that these continued headwinds can be partially mitigated by pricing actions, there can be no assurance that we will be able to continue to take such pricing actions."
• "We believe that our existing cash and cash equivalents, our anticipated cash flows from operations and amounts available under our line of credit will be sufficient to fund our anticipated operating and investment needs for at least the next 12 months."

Industry Context

The company operates in the highly competitive chiropractic industry, which is experiencing fundamental changes in how Americans access care, with a growing interest in affordable natural wellness solutions. There's also a preference among chiropractic doctors to move away from insurance-based models. The company's franchise model and refranchising strategy aim to capitalize on these trends, positioning itself as a leading provider. However, the industry faces broader macroeconomic challenges such as labor shortages and inflation, which impact operating costs and consumer discretionary spending on services.

Comparison to Industry Standards

• The filing does not provide specific comparisons to global benchmarks or named comparable companies/projects. It mentions that Adjusted EBITDA is commonly used for comparing companies in the industry, but does not offer a direct comparison of its own Adjusted EBITDA to industry averages or specific competitors' results.
• The company's refranchising strategy is a significant internal shift, but the filing does not benchmark this strategy against similar moves by other healthcare or franchise operators in terms of expected outcomes or efficiency.

Corporate Governance

Legal Proceedings

• The company entered into settlement agreements from litigation related to employment matters of $1.5 million during the second quarter of 2024, which has been accrued in discontinued operations current liabilities.
• A medical injury claim filed on September 5, 2023, reached a settlement agreement on February 25, 2025, for $3.4 million, paid in full during Q1 2025, with $1.9 million offset by a receivable from the company's insurance.

Related Party Transactions

• Mr. Jefferson Gramm, a managing partner of Bandera Partners LLC (beneficial holder of approximately 26% of common stock) and a Board Director, has a family member, Marshall Gramm, who owns four franchise licenses.
• One license was sold to Mr. Marshall Gramm in December 2020 for $39,900, and three licenses were transferred to him in June 2022 for a transfer fee of $15,000 each plus prorated franchise license fees of $17,706 total.
• These transactions were on terms no less favorable to the company than those obtained in the absence of such affiliation, and affiliated franchisees are subject to the same fees as all other franchisees.
• In October 2020, Mr. Gramm loaned approximately $370,000 to an unaffiliated franchisee, with a remaining balance of $270,800 as of March 31, 2025; the loan is unsecured and has no foreclosure rights.

Stakeholder Impact

• **Shareholders:** Face increased uncertainty and potential negative impact on stock price due to the restatement, material weakness in internal controls, and increased operating loss. The refranchising strategy, if successful, could offer long-term value, but immediate risks are high.
• **Employees:** The decrease in payroll and other employee compensation expenses, reflective of fewer employees and the departure of long-tenure employees, suggests potential workforce adjustments. Labor shortages are also a risk to operations.
• **Customers (Patients):** The company's focus on rapid expansion and the refranchising strategy aim to enhance service availability and brand recognition. However, potential impacts from labor shortages on service quality are a risk.
• **Franchisees:** The company's strategy is to grow through franchise sales and development, leveraging the regional developer program. However, a slowdown in new clinic openings and licenses sold could impact their growth prospects. The refranchising of corporate clinics could create new opportunities for existing or new franchisees.
• **Creditors:** The company was in compliance with all covenants under its Credit Agreement as of March 31, 2025, and has no outstanding balance. However, the material weakness in internal controls could raise concerns about financial stability and future access to financing.

Next Steps

• Management is in the process of developing a detailed remediation plan to address the identified material weakness in internal control over financial reporting.
• The remediation plan includes designing, implementing, and maintaining enhanced internal controls to timely analyze and account for non-routine, unusual, or complex transactions.
• The company will also design, implement, and maintain enhanced internal controls to timely review the application of valuation methodologies impacting impairment charges, including those for assets held for sale.
• The company expects to complete the refranchising of its corporate clinic portfolio within one year.
• The company plans to use or redeploy cash resources to support its business within prevailing market conditions for the remainder of 2025.
• The company will continue to evaluate the impact of macroeconomic factors like labor shortages and inflation on its business.

Key Dates

Recommendation

The restatement of financial statements and the identified material weakness in internal control over financial reporting are critical red flags for investors. While the restatement resulted in a higher net income, the underlying control deficiencies indicate significant issues with financial reporting reliability and corporate governance. The increase in operating loss from continuing operations and the slowdown in franchise development further compound these concerns. Despite the long-term refranchising strategy, the immediate risks associated with financial controls and operational performance warrant a 'sell' recommendation, as these issues can severely erode investor confidence and lead to further stock price volatility.

Keywords

SEC filing, 10-Q/A, Restatement, Material Weakness, Financial Reporting, Internal Controls, Chiropractic Clinics, Franchising, Refranchising Strategy, Asset Valuation, Discontinued Operations, Financial Performance, Revenue Growth, Operating Loss, Labor Shortage, Inflation, Corporate Governance, Investment Risk